Business Description
Redhill Biopharma Ltd
NAICS : 325412
ISIN : US7574681034
Share Class Description:
RDHL: ADRDescription
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.04 | |||||
| Debt-to-Equity | 9.15 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -18.01 | |||||
| Beneish M-Score | 10.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -75.8 | |||||
| 3-Year EPS without NRI Growth Rate | 72.1 | |||||
| 3-Year FCF Growth Rate | 63.5 | |||||
| 3-Year Book Growth Rate | -80.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 5.08 | |||||
| 9-Day RSI | 10.2 | |||||
| 14-Day RSI | 16.8 | |||||
| 3-1 Month Momentum % | -30.48 | |||||
| 6-1 Month Momentum % | -30.48 | |||||
| 12-1 Month Momentum % | -61.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.74 | |||||
| Quick Ratio | 0.56 | |||||
| Cash Ratio | 0.34 | |||||
| Days Inventory | 660.76 | |||||
| Days Sales Outstanding | 145.86 | |||||
| Days Payable | 417.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -174.6 | |||||
| Shareholder Yield % | 1441.27 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.18 | |||||
| Operating Margin % | -339.59 | |||||
| Net Margin % | 945.36 | |||||
| FCF Margin % | -329.47 | |||||
| ROE % | 2731.76 | |||||
| ROA % | 191 | |||||
| ROIC % | -82.71 | |||||
| 3-Year ROIIC % | -27.85 | |||||
| ROC (Joel Greenblatt) % | 3949.83 | |||||
| ROCE % | 1398.28 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.01 | |||||
| PE Ratio without NRI | 0.01 | |||||
| PS Ratio | 0.07 | |||||
| PB Ratio | 69.38 | |||||
| EV-to-EBIT | -0.04 | |||||
| EV-to-EBITDA | -0.02 | |||||
| EV-to-Forward-EBITDA | -3.75 | |||||
| EV-to-Revenue | -0.44 | |||||
| EV-to-Forward-Revenue | 1.37 | |||||
| EV-to-FCF | 0.13 | |||||
| Price-to-GF-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | -2500 | |||||
| FCF Yield % | -410.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RDHL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Redhill Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.395 | ||
| EPS (TTM) ($) | 504.826 | ||
| Beta | 5.45 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 51.37 | ||
| 14-Day RSI | 16.8 | ||
| 14-Day ATR ($) | 0.473244 | ||
| 20-Day SMA ($) | 5.22462 | ||
| 12-1 Month Momentum % | -61.63 | ||
| 52-Week Range ($) | 3.01 - 20.275 | ||
| Shares Outstanding (Mil) | 1.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Redhill Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Redhill Biopharma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Redhill Biopharma Ltd Frequently Asked Questions
What is Redhill Biopharma Ltd(RDHL)'s stock price today?
The current price of RDHL is $3.33. The 52 week high of RDHL is $20.27 and 52 week low is $3.01.
When is next earnings date of Redhill Biopharma Ltd(RDHL)?
The next earnings date of Redhill Biopharma Ltd(RDHL) is 2025-03-05 Est..
Does Redhill Biopharma Ltd(RDHL) pay dividends? If so, how much?
Redhill Biopharma Ltd(RDHL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers